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Cardiomyopathies are common cardiac disorders that primarily aﬀect cardiac muscle resulting in cardiac dysfunction and heart
failure. Transgenic mouse disease models have been developed to investigate the cellular mechanisms underlying heart failure and
sudden cardiac death observed in cardiomyopathy cases and to explore the therapeutic outcomes in experimental animals in vivo.
Echocardiography is an essential diagnostic tool for accurate and noninvasive assessment of cardiac structure and function in
experimental animals. Our laboratory has been among the ﬁrst to apply high-frequency research echocardiography on transgenic
mice with cardiomyopathies. In this work, we have summarized our and other studies on assessment of systolic and diastolic
dysfunction using conventional echocardiography, pulsed Doppler, and tissue Doppler imaging in transgenic mice with various
cardiomyopathies.Estimationofembryonicmouseheartshasbeenperformedaswellusingthishigh-resolutionechocardiography.
Some technical considerations in mouse echocardiography have also been discussed.
1.Introduction
Cardiomyopathieshavebeenconsideredtorepresentdiseases
that primarily aﬀect cardiac muscle. On the ground of their
morphology and pathophysiology, cardiomyopathy may be
classiﬁed into three major types: hypertrophic cardiomyopa-
thy (HCM), dilated cardiomyopathy (DCM), and restrictive
cardiomyopathy (RCM). In the past, most cardiomyopathy
cases were described as idiopathic cardiomyopathies, that is,
etiology is unknown [1, 2]. Now, we know that most car-
diomyopathy cases are heritable [3] and several mutations in
cardiac muscle genes, such as myosin, tropomyosin, cardiac
troponin T (cTnT), and cardiac troponin I (cTnI) have been
identiﬁed to be associated with cardiomyopathies [4–7].
Clinical studies showed great heterogeneity among the
genetic cardiomyopathic patients even when they carry the
same mutation [8–11]. The biggest challenge is that no data
are available so far to conﬁrm the overall expression and the
incorporation rate of the mutant sarcomeric proteins in the
heart. Furthermore, other environmental and genetic factors
may also contribute to the heterogeneity of the disease mani-
festation. Recently, transgenic animal models have been gen-
erated to mimic various cardiomyopathies by expressing the
mutant cardiac myoﬁbril proteins observed in human
patients [12, 13]. Studies with transgenic animals will ﬁll the
gap in cardiomyopathy research between the in vitro assays
using reconstituted myoﬁbrils and the clinical studies with
the patients carrying the mutant genes, which will undoubt-
edly improve our understanding of the mechanisms under-
lying the cardiomyopathies and provide us with clues for the
prevention and treatment of the diseases.
In general, in the case of DCM, heart failure is character-
ized by systolic dysfunction (i.e., reduced ejection fraction),
whereas HCM and RCM are characterized by diastolic
dysfunction (i.e., impaired relaxation) [14]. To evaluate the
phenotypes, it is necessary to develop accurate, reproducible,
and noninvasive methods to assess cardiac morphology and
function in a serial manner. Ultrasound imaging has been
increasingly applied to identify and characterize structural
and functional features of diﬀerent cardiac phenotypes in2 Biochemistry Research International
large animals modeling human diseases [15]. Although the
acquisition of mouse echocardiograms is relatively simple,
echocardiographic studies are challenging because of the
small size, rapid heart beating rate, and orientation of the
mouse heart. Recently, a high-resolution echocardiograph
has been developed with high-frequency (30–50MHz) and
high-frame rate mechanical probes, allowing an axial resolu-
tion of approximately 50µma tad e p t ho f5 – 1 2c m[ 16]. Our
laboratoryhasbeenamongtheﬁrsttoassesscardiacfunction
using the high-frequency echocardiograph (VisualSonics,
Inc. Toronto, Canada) on transgenic mice with various
cardiomyopathies. In this review, we will summarize the
application of the conventional echocardiography, pulsed
Doppler, and tissue Doppler imaging for cardiac function
assessment in mice and discuss several technical considera-
tions in mouse echocardiography.
2. Echocardiography Measurementand
MajorParameters
The conventional echocardiography is applied in our labo-
ratory on experimental mice. In addition, pulsed Doppler
and tissueDoppler imaging (TDI)arealso used todetermine
hemodynamicsandthemyocardialmotion.B-modeisatwo-
dimensional real-time image of the heart, which is used to
visualize and quantify the anatomical structures. A four-
chamber image including left and right atria and ventricles
can be obtained from the B-mode. Usually, the operator ﬁrst
locatesthestructurebyB-modethenchangestoothermodes
to measure the cardiac wall motion or blood ﬂow. M-mode
is the temporal image of cardiac wall motion along a single
ultrasound beam, which enables the quantiﬁcation of wall
thickness and cavity dimensions as well as the movement
of myocardium, valves, and vessel walls. Usually, left ven-
tricular end diastolic dimension (LVEDD) and end systolic
dimension (LVESD), interventricular septum (IVS), and
posterior wall (PW) thickness are recorded with M-mode.
Shortening fraction (SF) is calculated from the M-mode LV






where SF is an index of systolic left ventricular function.
PulsedDopplerimagingisprimarilyusedforthequantitative
measure of blood ﬂow through valves, arteries, or veins,
which provides information of both the direction and the
velocity of blood ﬂow. Tissue Doppler provides the quantiﬁ-
able information of myocardial tissue movement, for exam-
ple, the movement of valves. The major parameters in pulsed
Doppler and tissue Doppler measurements will be described
in the following sections.
3. Assessment of SystolicFunction
Left ventricular structure and systolic function is most
commonly measured by M-mode in a parasternal short
axis view at the papillary muscle level. In order to obtain
ananatomicallycorrectparasternalshortaxisview,operators
usually start with parasternal long axis view by placing the
transducer vertically to the animal body on the left side of
its sternum with the “notch” of transducer pointing to the
animal head; and then rotating approximately 30–45 degrees
counterclockwise. This view depicts the mid-portion and
base of the left ventricle, both leaﬂets of the mitral valve, the
aortic valve and aortic root, the left atrium, and the right
ventricle. The parasternal short axis view is obtained by
rotatingthetransducerthrough90degreesclockwisebaseon
the long axis view. Then, the transducer is tilted a little to
the apex to visualize the papillary muscles. To ensure all the
measure is reliable and repeatable, the short axis view at pap-
illary muscle level is required as a criterion for the imaging
used in the later M-mode measure. In other words, the left
ventricle is sectioned across the middle of papillary muscles
a n dv i s u a l i z e da sac o m p l e t e l yr o u n dv i e wo fi t .T h el e f t
ventricular wall motion along the sampling line is recorded
and analyzed in M-mode (Figure 1).
With M-mode imaging of the left ventricle, investigators
are able to directly measure the thickness of left ventricular
posterior and anterior walls and the interventricular septum.
Theincreaseinthewallthicknessindicatesventricularhyper-
trophy while the decrease might be observed in ventricular
dilation. Left ventricular mass can be calculated based on
the wall thickness. Left ventricular chamber diameter at end-
diastole and end-systole is also able to be directly measured.
As mentioned above, FS can be calculated from the M-mode
LV dimensions. In addition, ejection fraction (EF) is another
useful index of systolic function, which can be calculated as
well from the M-mode measurements.
Pulsed Doppler imaging has been used as well to assess
the blood ﬂow through aorta. The quantitative data of the
blood ﬂow peak velocity, velocity time integral, the peak,
and mean gradient can be measured or calculated, which
p r o v i d eu sw i t hu s e f u li n f o r m a t i o no ns y s t o l i cf u n c t i o n
of experimental animals (Figure 2). Aortic root can be
visualized under apical ﬁve-chamber view, the ﬁfth chamber
isaorta.Whenthetransduceristiltedupwardfromtheapical
four-chamber view, aorta will be seen in the middle of the
screen (Figure 2).
An Example of Transgenic Disease Mouse Model with Systolic
Dysfunction. We performed echocardiography studies to
measure the cardiac function of cTnT-DE7 transgenic mice
(6-month-old) that express an abnormal splice-out of the
exon7-encodedsegmentintheN-terminalvariableregionof
cardiac troponin T in the hearts. No atrial enlargement, ven-
tricular hypertrophy, or dilation was detected in the hearts
of 3-months-old cTnT-DE7 mice, indicating a compensated
state. However, left ventricular FS and EF were signiﬁcantly
decreased in 6-month-old cTnT-DE7 mice compared to
wild-type controls. Furthermore, the left ventricular outﬂow
tract velocity and gradient were both signiﬁcantly decreased
in the transgenic mouse hearts, indicating decreased systolic
function. The impaired systolic heart function in vivo
without detected changes in diastolic function suggests that
cTnT-DE7 primarily reduces contractile function of the
cardiac muscle ([17] and unpublished data).Biochemistry Research International 3
Figure 1: M-mode imaging obtained on a wild type mouse using a 30-MHz transducer.
Figure 2: Aortic pulse Doppler tracings obtained on a wild-type mouse.
4. Assessment of DiastolicFunction
In general, cardiac diastolic function can be assessed with
conventional echocardiography in B-mode and M-mode. B-
mode clearly shows the structure of left ventricle and the
dimensionoftheleftventricleduringthesystoleanddiastole.
M-mode, furthermore, provides the ability to obtain
anatomically correct LV measurements, such as LVESD and
LVEDD. Using B-mode and M-mode, we observed a signiﬁ-
cantly reduced LV end-diastolic dimension in cTnI knockout
mice and RCM cTnI transgenic mice, both suﬀering from a
severe diastolic dysfunction [12, 18].4 Biochemistry Research International
Figure 3: Mitral pulse Doppler tracings obtained on a wild type mouse. E, E wave indicating early ventricular ﬁlling; A, A wave indicating
late ﬁlling caused by atrial contraction; ET, ejection time; IVRT, isovolumetric relaxation time; IVCT, isovolumetric contraction time; DT,
deceleration time.
Recently, Doppler echocardiography has emerged as an
important clinical tool to provide reliable and useful data
for diastolic performance [15, 19]. The noninvasive nature
and high-resolution feature of Vevo 770 echocardiography
allow us to longitudinally monitor diastolic performance in
mice in vivo. Using echocardiography to evaluate diastolic
function is primarily achieved via pulsed Doppler imaging of
transmitral blood ﬂow and tissue Doppler imaging of mitral
annulus velocity. They are all accessed under apical four-
chamber view, which is obtained from the lower left side of
theanimal’sthorax.Thisviewessentiallyallowsustolookup
from the apex towards the base of the heart and visualize the
right and left ventricles, and the mitral inﬂow tract, with the
atria at the bottom of the screen (Figure 3). Thetransduceris
angled by 60–70 degrees and placed in a transverse position
with the notch facing the left side of the mouse.
As shown in Figure 3, two diastolic waves, E and A, are
seen in normal mitral Doppler tracing. The E wave occurs
during the rapid ﬁlling phase in early diastole and the A
wave occurs in late diastole as a result of atrial contraction.
Normally, the E wave is higher than the A wave. Clinically
useful mitral inﬂow parameters include the following: early
ﬁlling peak velocity (E); atrial peak velocity (A); E/A ratio
(normally >1); deceleration time (DT) or the interval
between the peak of the E wave to the zero baseline. The
isovolumetric relaxation time (IVRT) is also measured and
is the phase in which all valves are closed and the ventricles
relax without any change in volume.
TDI analysis has become an established component of
the diagnostic ultrasound examination, which permits an
assessment of myocardial motion. Sample volume is mea-
sured at the septal side of the mitral annulus. Early (E )a n d
late (A ) diastolic mitral annulus velocity and the ratio of E 
to A  are determined. TDI is very useful to distinguish the
pseudo-normalization pattern from the normal ﬁlling pat-
tern as reported previously [20].
The ratio of early ﬁlling transmitral peak velocity (E)
o v e rt h eT D Im i t r a lv a l v eEv e l o c i t y( E  ) has established itself
as a reliable guide to elevated pulmonary capillary wedge
pressure [21]. Pulmonary capillary wedge pressure (PCWP)
provides an indirect estimate of left atrial pressure [22].
Althoughleftventricularpressure(LAP)canbedirectlymea-
sured by placing a catheter into the left ventricle by feeding
it through a peripheral artery, into the aorta, and then into
the ventricle, it is not feasible to advance this catheter back
intotheleftatrium.LAPcanbemeasuredbyplacingaspecial
catheter into the right atrium then punching through the
interatrial septum; however, for obvious reasons, this is notBiochemistry Research International 5
usually performed because of the damage to the septum.
Direct measurement of LAP can be available to human
hearts, but it is not applicable to mouse hearts. Therefore,
the E/E  ratio for estimation of LAP in mouse hearts is a very
useful tool in the assessment of cardiac diastolic properties.
An Example of Transgenic Disease Mouse Model with Diastolic
Dysfunction. We applied both pulsed Doppler and TDI to
ourstudiesontransgenicmice(from2–12months)suﬀering
from restrictive cardiomyopathy due to cTnI mutation [20,
23]. We found an E/A ratio reverse representing a relaxation
abnormality in these transgenic mice and restrictive physiol-
ogy in these mice at the advanced stage [20]. Furthermore,
we found that prolongation of IVRT was the earliest sign
of impaired relaxation observed in these transgenic mice.
This is consistent with previous reports demonstrating that
IVRT is the most sensitive Doppler index to detect impaired
relaxation because it is ﬁrst to become abnormal [24, 25].
5. Assessment of CoronaryFlow and
MyocardialPerfusion
Pulsed Doppler imaging has been used to assess the blood
ﬂow through coronary artery of mouse hearts [26]. From
a modiﬁed parasternal long axis view, the left coronary
artery is visualized stemming from the aorta sinus, traveling
between the right ventricle outﬂow tract and left ventricular
anterior wall, and along the left ventricular wall to the distal
branch site (Figure 4). Sample volume of pulsed Doppler
is placed on the left main coronary artery. Under such
condition, Doppler imaging of coronary blood ﬂow consists
of two peaks: the preceding low peak representing coronary
blood ﬂow in systole and the following high peak represent-
ing the coronary perfusion in diastole (Figure 4).
We measured coronary artery blood ﬂow using echocar-
diography Doppler system in wild-type and transgenic
mice (2-month-old) with diastolic dysfunction. Our results
showed that a signiﬁcant decrease of coronary circulation
was observed in transgenic mice suﬀering from diastolic
dysfunction (unpublished data). These data indicate that
the increased atrial and ventricular end-diastolic pressure
observed in diastolic dysfunction can reduce coronary artery
blood ﬂow since the coronary blood supply occurs mostly
during the diastole. Hartley et al. also reported that a signiﬁ-
cant reduction of coronary ﬂow reserve (CFR) was observed
using noninvasive 20-MHz Doppler ultrasound in mice with
pressure overload cardiac hypertrophy [27]. Echocardio-
graphic techniques are, indeed, useful tools for assessing
coronary blood ﬂow and myocardial perfusion in mice in
vivo.
6. Examinationof EmbryonicMouse Hearts
Although technically challenging, evaluation of the cardiac
d i m e n s i o na n df u n c t i o no fm o u s ee m b r y o si sa ni n v a l u a b l e
tool to assess the role of genes in the early development of
cardiac function [16]. We have examined embryonic mouse
hearts using high-resolution echocardiography in B-mode
and M-mode. The earliest detection is available on embry-
onic day 8.5 (E8.5) when the linear heart tube begins to
beat. During days E11.5 to 13.5, it is possible to observe atria
and ventricles since heart separation is taking place. On day
E14.5, it is feasible to measure the ventricular wall thickness
and the motion with high-resolution echocardiography in
M-mode. From day E14.5 onward, we can examine the four-
chamber embryonic heart morphology, analyze the cardiac
function, and detect the abnormality in the heart during the
development (Figure 5).
7. Technical Considerations in
MouseEchocardiography
Cautionary tales of mouse echocardiography have been
discussed by several reviews [15, 16, 28]. The common
issue is anesthesia and mouse heart rates. Anesthetic agents
are generally employed to immobilize and sedate mice for
better image acquisition during echocardiographic exami-
nation. Heart rate in conscious normal mice is about 600–
650 beats/minute. The reduction in heart rate caused by
anesthetics in diﬀerent research models may result in better
temporal resolution for improved image visualization, and
measurement,butmay simultaneously confoundthe physio-
logical issue in question [15]. In our studies, we initially used
a protocol of anesthesia that mice were anesthetized with 5%
isoﬂurane and then maintained at 1.5% isoﬂorane by a face-
mask during the whole procedure. It has been reported that
using 1.5% isoﬂurane for anesthesia has minimal eﬀects on
cardiac function [29, 30]. However, we observed late that we
could reduce the isoﬂorane concentration to 1% that could
maintain the experimental mice immobile with heart rates
around 470–500 beats/min during the procedure. However,
when the heart rate is over 450 beats/min, it is challenging
to obtain the separated E and A waves in pulsed Doppler
imaging even using the high-resolution echocardiography.
According to our experience, we can diﬀerentiate E and A
waves in pulsed Doppler imaging from experimental mice
when their heart rate is controlled around at 400beats/min.
To avoid possible inﬂuence of varied heart rates on the
explanations of physiological ﬁndings, the key point here is
to observe and analyze cardiac function with echocardiog-
raphy on all experimental mice (including transgenic and
wild type control mice) at a similar and comparable heart
rate.
In addition, we ﬁnd that prewarming ultrasound trans-
mission gel and keeping the experimental platform at 37◦C
arenecessarytomaintainthestablemousebodytemperature
and heart rate during the procedure of echocardiography
measurements.
8. Conclusions
Transgenic mice displaying various cardiomyopathies asso-
ciated with cardiac sarcomeric protein mutations represent
a powerful tool for understanding the mechanisms under-
lying the initiation and the development of the diseases.6 Biochemistry Research International
Figure 4: Coronary pulse Doppler tracings obtained on a wild-type mouse.
High- frequency research echocardiography and pulsed
Doppler imaging provide us with a noninvasive and reliable
method for the assessment of cardiovascular structural and
functional changes in cardiomyopathy mouse models and
other murine models. The application of fetal mouse imag-
ing using the high-frequency research echocardiography will
open a new way for the studies on fetal cardiac physiology
and heart development in mouse models.
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Figure 5: Echocardiographic observations on embryonic mouse heart during the development. Echocardiographic images obtained on
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